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Abstract
Background: The phase III REMoxTB study prospectively enrolled HIV-positive (with CD4+ count > 250 cells, not on
anti-retroviral therapy) and HIV-negative patients. We investigated the incidence of adverse events and cure rates
according to HIV status for patients receiving standard TB therapy in the trial.
Methods: Forty-two HIV-positive cases were matched to 220 HIV-negative controls by age, gender, ethnicity, and
trial site using coarsened exact matching. Grade 3 and 4 adverse events (AEs) were summarised by MedDRA
System Organ Class. Kaplan-Meier curves for time to first grade 3 or 4 AE were constructed according to HIV status
with hazard ratios calculated. Patients were considered cured if they were culture negative 18 months after
commencing therapy with ≥2 consecutive negative culture results.
Results: Twenty of 42 (47.6%) HIV-positive and 34 of 220 (15.5%) HIV-negative patients experienced ≥1 grade 3 or 4
AE, respectively. The majority of these were hepatobiliary disorders that accounted for 12 of 40 (30.0%) events
occurring in 6 of 42 (14.3%) HIV-positive patients and for 15 of 60 (25.0%) events occurring in 9 of 220 (4.1%) HIV-
negative patients. The median time to first grade 3 or 4 AE was 54 days (IQR 15.5–59.0) for HIV-positive and 29.5
days (IQR 9.0–119.0) for HIV-negative patients, respectively. The hazard ratio for experiencing a grade 3 or 4 AE
among HIV-positive patients was 3.25 (95% CI 1.87–5.66, p < 0.01). Cure rates were similar, with 38 of 42 (90.5%)
HIV-positive and 195 of 220 (88.6%) HIV-negative patients (p = 0.73) cured at 18 months.
Conclusions: HIV-positive patients receiving standard TB therapy in the REMoxTB study were at greater risk of
adverse events during treatment but cure rates were similar when compared to a matched sample of HIV-negative
patients.
Keywords: Tuberculosis, Clinical trials, HIV, Adverse events
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: c.tweed@ucl.ac.uk
1MRC Clinical Trials Unit at University College London, London, UK
Full list of author information is available at the end of the article
Tweed et al. BMC Pulmonary Medicine          (2019) 19:152 
https://doi.org/10.1186/s12890-019-0907-6
Introduction
Infection with the human immunodeficiency virus (HIV)
continues to act as a major driver of the global tubercu-
losis (TB) epidemic [1, 2]. HIV infection results in
greater chance of developing active TB by causing a
widespread impairment of the body’s immune system
[3]. HIV-positive patients have been shown to be more
likely to be sputum smear negative [4, 5], and have fewer
cavities on chest X-ray [6, 7]. This is thought to reflect
the frequently lower bacillary burden in co-infected indi-
viduals [8], translating into a delay in the diagnosis of
TB in HIV-positive patients [9, 10], with longer time be-
tween onset of disease and initiation of treatment lead-
ing to worse treatment outcomes [11, 12].
There is an increased risk of toxicity in HIV-positive
patients being treated for active TB [13–16], and higher
rates of treatment failure and relapse have been de-
scribed in anti-retroviral therapy (ART)-naïve HIV-posi-
tive patients being treated for active TB [17–19]. The
overall risk of treatment failure is reduced in the context
of adherence to ART [17, 20] and the World Health Or-
ganisation has recommended ART as early as possible
for all HIV-infected patients since 2016 [21], but despite
significant gains in the roll-out of ART globally there are
still many areas where treatment coverage is below 50%
[22]. Clinicians in settings with limited availability of
ART need an accurate understanding of the expected
course for patients on treatment, including the incidence
of toxicity, to ensure that they react in an appropriate
manner to indicators of poor outcome.
We have used the efficacy and safety data collected for
patients receiving standard TB therapy as part of the
REMoxTB study to obtain a detailed picture of the inci-
dence of treatment-related toxicity and cure rates ac-
cording to HIV status. The baseline characteristics for
HIV-positive patients were compared to HIV-negative
patients randomised in the trial, response to treatment
was investigated using measured variables, and the na-
ture of toxicity on treatment and the impact on treat-
ment outcomes compared for patients with and without
HIV infection.
Methods
Baseline characteristics and matched patient sample
The baseline characteristics for all randomised patients
across the treatment arms in REMoxTB were compared
to determine any significant differences. Characteristics
from before the initiation of treatment were collected
for HIV-positive and HIV-negative patients. Patients tak-
ing ART at screening were screened out, however, files
in the dataset relating to concomitant medications were
used to determine the number of patients started on
ART during the trial and the timing of initiation. ART
initiation was at the discretion of the treating physician,
in keeping with best practice at the time, and current
ART use was an exclusion criteria for patients being
screened for the trial.
Coarsened exact matching (CEM) [23, 24] was used to
create a population of HIV positive cases matched to
HIV negative controls, all treated with standard TB
therapy. Standard TB therapy was defined as 2 months
of isoniazid, rifampicin, pyrazinamide, and ethambutol
followed by 4 months of isoniazid and rifampicin alone.
Age, gender, ethnicity and trial site were selected as the
matching variables to give the maximum number of
matching variables with the greatest number of HIV-
positive patients matched.
Toxicity during treatment
The number of HIV-positive and HIV-negative patients
who experienced ≥1 grade 3 or 4 adverse event (AE) was
calculated for both the total grade 3 or 4 AEs (as per the
DAIDS criteria) and only for those that were considered
related to treatment by the reporting clinician. Grade 3
or 4 AEs with and without recorded start dates were in-
cluded when identifying these patients and events were
collated according to System Organ Class (SOC).
Longitudinal analysis of the matched population
The mean value was calculated for haemoglobin result,
patient weight, number of TB symptoms reported and
alanine transferase (ALT) result at protocol-scheduled
visits for HIV-positive and HIV-negative patients in the
matched population. Blood samples were collected at
weeks 0, 2, 8, 12, and 17 routinely for all patients.
Weight and number of TB symptoms reported was doc-
umented for each protocol-scheduled visit during enrol-
ment in the trial. The mean value for each variable was
calculated for each scheduled visit and measurements
taken at unscheduled visits were discarded as these
would tend to occur around adverse events.
Treatment outcomes
The “first sustained negative culture” was defined as the
first negative Mycobacterial Growth Indicator Tube
(MGIT) culture with a subsequent negative culture col-
lected a minimum of 1 week later with no positive cul-
tures in between. The median time to sustained negative
culture was calculated for HIV-positive and HIV-nega-
tive patients in the matched sample, and Kaplan-Meier
curves were constructed for the time to first sustained
negative culture in both patient groups.
Patients were then assigned into groups based on
whether they achieved a microbiological cure. A com-
posite culture status at 18 months, requiring negative
cultures on both Lowell-Johnson (LJ) slopes and MGIT
culture to be considered culture negative, was available
and patients who were culture negative at 18 months
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were labelled as “cured”. If a patient was lost to follow
up, or died before 18 months in the trial, then they were
considered cured if they had completed their treatment
and had two or more consecutive negative cultures (at
different visits) prior to the date that they were last seen.
Those patients who were culture positive at 18 months,
or who were lost to follow up or died with less than two
consecutive negative cultures immediately prior, were
considered not cured for this analysis.
Statistical methods
All data manipulation and analysis was carried out using
Stata version 14 (StataCorp, Texas) and statistical signifi-
cance was set at 5% for all tests. The Chi Square test
was used to test for significant differences between sam-
ple proportions.
Kaplan-Meier curves were constructed for time to
event analyses, and the logrank test was used to test for
significant difference in the time to event between
groups. Hazard ratios were generated using Cox regres-
sion comparing groups where a significant difference
was detected using the logrank test and Schoenfeld re-
siduals confirmed the proportional hazard assumption.
Generalised estimation equations (GEEs) were used to
investigate the association between HIV status and the
longitudinal change in haemoglobin, weight, symptom
count, and ALT results using a Gaussian distribution
and exchangeable correlation matrix. Weeks after first
dose of treatment, a multiple of week number and HIV
status (to test interaction) were included as predictors,
along with the squared value of the week number.
Zellner’s seemingly unrelated regression [25] was used
to build a multivariate model testing the effect of HIV
status (as the exposure variable) on the first and last
haemoglobin, weight, TB symptom count, and ALT re-
sults (as outcome variables). This multivariate regression
method uses simultaneous generalised linear regression
on a number of outcomes of interest in relation to one
or more exposure variables, but there is an assumption
that the covariance for the error terms between the indi-
vidual linear regression models is non-zero. To allow for
a more appropriate comparison of variables in the
model, the screening value and the result at week 17
were used as all variables had these time points routinely
measured.
Ethics approval and participant consent
The REMoxTB study was carried out with approval from
the ethics board at University College London and the
local ethics boards at each of the sites where patients
were treated. This included approval for the use of data
and samples collected in other studies to improve the
diagnosis and treatment of tuberculosis. All randomised
patients agreed to any data and samples collected as part
of the trial being used in further studies to improve the
diagnosis and treatment of tuberculosis, as stated on the
informed consent form for the study. All the research
activities and data collection for the study was compliant
with the Helsinki Declaration and the principles of Good
Clinical Practice.
Results
Baseline characteristics for all randomised patients
The baseline characteristics for all randomised patients
in the REMoxTB study are presented in Table 1 accord-
ing to HIV status. There were 37 of 140 (26.4%) HIV-
positive patients and 349 of 1790 (19.5%) HIV-negative
patients with no cavitation seen on chest X-ray (p value
0.02). However, the proportion of patients with a time to
culture positivity in liquid medium (TTP) less than the
median value for the total analysis sample was similar ir-
respective of HIV status: 73 of 140 (52.1%) of HIV-posi-
tive and 841 of 1790 (47.0%) HIV-negative patient
sputum samples (p value 0.24).
Matched population of HIV-positive and HIV-negative
patients assigned to standard TB therapy
Coarsened exact matching (CEM) produced a matched
population of 42 HIV-positive cases to 220 HIV-negative
controls all receiving standard TB therapy in REMoxTB
using the matching variables (see Table 2). There were 4
HIV-positive cases that could not be adequately matched
to HIV-negative controls. The L1 statistic indicates the
measure of global balance between perfect global bal-
ance (L1 = 0) and complete separation between the
matching variables (L1 = 1). The multivariate L1 statistic
was 0.152 which indicated overall low global imbalance.
The median CD4+ cell count among the HIV-positive
patients was 370 cells per mm3 (IQR 307–456). Only 10
HIV-positive patients were started on ART following
commencing therapy into the trial at a median time of
180 days, with no patients starting ART in the first 8
weeks of standard TB therapy.
Toxicity during treatment in the matched patient sample
A total of 20 of the 42 (47.6%) HIV-positive patients ex-
perienced ≥1 grade 3 or 4 AE, as opposed to 34 of the
220 (15.5%) HIV-negative patients. One or more grade 3
or 4 AE considered to be at least possibly related to
treatment was reported by 11 of 42 (26.2%) HIV positive
patients and 14 of 220 (6.4%) HIV-negative patients. The
majority of these were hepatobiliary disorders that
accounted for 12 of 40 (30.0%) events occurring in 6 of
42 (14.3%) HIV-positive patients and for 15 of 60
(25.0%) events occurring in 9 of 220 (4.1%) HIV-negative
patients (see Table 3).
The hazard ratio for experiencing a grade 3 or 4 AE
for HIV-positive patients was significantly elevated
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compared to HIV-negative patients at 3.25 (95% CI
1.87–5.66, p value < 0.01), and remained significant for
related-only grade 3 or 4 AEs (HR 3.77, 95% CI 1.65–
8.60, p value < 0.01). Figure 1 presents Kaplan-Meier
curves for the time to first grade 3 or 4 AE based on
HIV status. The median time to first grade 3 or 4 AE
was 54 days (IQR 15.5–59.0) for HIV positive patients
and 29.5 (IQR 9–119) for HIV negative patients. This
was 56 days (IQR 29–57) for HIV-positive patients and
50 days (IQR 19–56) for HIV-negative patients for re-
lated-only events.
Longitudinal analysis of the matched population assigned
to standard TB therapy
The mean haemoglobin at the beginning of treatment
was 0.89xLLN and 1.00xLLN at week 17 among HIV-
positive patients, and 0.93xLLN and 1.08xLLN at the
same time points for HIV-negative patients. The mean
weight gain from baseline to week 26 was 3.16 kg for pa-
tients infected with HIV and 4.82 kg among HIV-
Table 2 Baseline characteristics of matched patients in analysis
sample from REMoxTB according to HIV status. The column
percentages included in cells indicate the proportion of total n
in for HIV-positive and HIV-negative patients belonging to
categories of baseline characteristic. Chi square p values
comparing the proportions of patients with each characteristic
according to HIV status are also provided. *Median time to
MGIT culture positive result for all patients = 109 h
n HIV-positive HIV-negative P value
42 220
Gender
Male 23 (54.8%) 154 (70.0%) 0.053
Female 19 (45.2%) 66 (30.0%)
Age in Years
< 25 4 (9.5%) 40 (18.2%) 0.379
25–35 17 (40.5%) 84 (38.2%)
> 35 21 (50.0%) 96 (43.6%)
Baseline Weight
< 40 2 (4.8%) 9 (4.1%) 0.965
40–45 7 (16.7%) 39 (17.7%)
> 45–55 16 (38.1%) 83 (37.7%)
> 55–75 15 (35.7%) 83 (37.7%)
> 75 2 (4.8%) 6 (2.7%)
Ethnicity
Black 38 (90.5%) 186 (84.6%) 0.583
Asian 2 (4.8%) 20 (9.1%)
Other 2 (4.8%) 14 (6.4%)
Smoking Status
Never 18 (42.9%) 114 (51.8%) 0.309
Previous 11 (26.2%) 61 (27.7%)
Current 13 (31.0%) 45 (20.5%)
Chest X-ray
Cavities 26 (61.9%) 160 (72.7%) 0.062
No cavities 11 (26.2%) 32 (14.5%)
MGIT TTP
≥ Median 22 (52.4%) 118 (53.6%) 0.881
< Median 20 (47.6%) 102 (46.4%)
Table 1 Baseline characteristics of all randomised patients for
REMoxTB according to HIV status. The column percentages
included in cells indicate the proportion of total n in for HIV-
positive and HIV-negative patients belonging to categories of
baseline characteristic. Chi square p values comparing the
proportions of patients with each characteristic according to
HIV status are also provided. *Median time to MGIT culture
positive result for all patients = 118 h
n HIV-positive HIV-negative P value
140 1790 –
Gender
Male 78 (55.7%) 1267 (70.8%) < 0.001
Female 62 (44.3%) 523 (29.2%)
Age in Years
< 25 20 (14.3%) 545 (30.5%) < 0.001
25–35 60 (42.9%) 546 (30.5%)
> 35 60 (42.9%) 699 (39.0%)
Baseline Weight
< 40 4 (2.9%) 17 (9.6%) < 0.001
40–45 15 (10.7%) 311 (17.4%)
> 45–55 50 (35.7%) 716 (40.0%)
> 55–75 65 (46.4%) 552 (30.8%)
> 75 6 (4.3%) 40 (2.2%)
Ethnicity
Black 128 (92.1%) 734 (41.0%) < 0.001
Asian 3 (2.2%) 587 (32.8%)
Caucasian 0 (0.0%) 3 (0.2%)
Other 8 (5.8%) 8 (5.8%)
Smoking Status
Never 70 (50.0%) 800 (44.7%) 0.141
Previous 38 (27.1%) 438 (24.5%)
Current 32 (22.9%) 552 (30.8%)
Chest X-ray
Cavities 80 (57.1%) 1247 (69.7%) 0.015
No cavities 37 (26.4%) 349 (19.5%)
MGIT TTP*
≥ Median 67 (47.9%) 949 (53.0%) 0.239
< Median 73 (52.1%) 841 (47.0%)
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negative patients in the matched sample. HIV-positive
patients had a mean weight of 55.81 kg at the beginning
of their treatment and 62.05 kg at week 78, compared to
a mean weight of 53.61 kg at baseline and 61.19 kg at
week 78 in HIV-negative patients.
Table 4 demonstrates the frequency of the 10 most
commonly-reported symptoms according to HIV status.
There were 21 of 42 (50.0%) HIV-positive patients
reporting ≥1 TB-related symptoms at baseline with a
mean of 5.19 symptoms reported per patient. Among
the HIV-negative patients, 126 of 220 (57.3%) reported
≥1 symptom in keeping with active TB and there was a
mean of 4.60 symptoms recorded per patient.
The mean ALT result at week 8 was 1.10xULN and
0.68xULN for HIV-positive and HIV-negative patients,
respectively. At week 12, the mean ALT was 1.25xULN
for HIV-positive patients and 0.61xULN for HIV-nega-
tive patients.
Of these four variables, only haemoglobin was sig-
nificantly associated with HIV status in a generalised
estimation equation (coef − 0.05, 95% CI [− 0.098] –
[− 0.003], p value 0.04). Multivariate regression of
the above variables at week 0 and week 17 against
HIV status as an exposure variable did not demon-
strate any statistically significant associations (see
Table 5).
Treatment outcomes in the matched patient samples
The median time to the first sustained negative MGIT
culture was 84 days (IQR 49–123) for HIV-positive pa-
tients and 73 days (IQR 49.5–172) in HIV-negative pa-
tients assigned to standard TB therapy. No significant
Table 3 System Organ Classes (SOCs) for the five most frequently reported grade 3 or 4 Adverse Events (AEs) reported by HIV-
positive and HIV-negative patients in the matched population during enrolment in the REMoxTB trial. Total number of grade 3 or 4
adverse events of the SOC shown according to HIV status and percentage of total number of grade 3 or 4 AEs in HIV group
provided in brackets
Adverse Event SOC HIV-positive Patients (% of G3+ Events) HIV-negative Patients (% of G3+ Events)
Hepatobiliary disorders 12 (30.0%) 15 (25.0%)
Respiratory and thoracic disorders 7 (17.5%) 13 (21.7%)
Blood and lymphatic disorders 6 (15.0%) 10 (16.7%)
Infections and infestations 3 (7.5%) 5 (8.3%)
Metabolism and nutrition disorders 3 (7.5%) 4 (6.7%)
Other 9 (17.5%) 13 (16.7%)
Fig. 1 Kaplan-Meier curves demonstrating the time to first related or unrelated grade 3 or 4 adverse event according to patient HIV status in the
matched sample. There were 3 HIV-positive and 42 HIV-negative patients who experienced ≥1 grade 3 or 4 adverse event for whom none of the
events had an associated start time, and they were excluded from the KM curve. The hazard ratio for HIV-positive patients experiencing ≥1 grade
3 or 4 adverse event was significantly elevated at 3.25 (95% CI 1.87–5.66, p value < 0.01)
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difference was detected in the time to first sustained
negative culture between HIV-positive and HIV-negative
patients (logrank p value 0.60).
There were 4 of 42 (9.5%) of HIV-positive patients
who failed to achieve microbiological cure and 25 of 220
(11.4%) HIV-negative patients in the matched sample (p
value 0.73). There were 4 of 38 (10.5%) HIV-positive
and 8 of 195 (4.1%) HIV-negative were withdrawn from
treatment in the trial and referred to the National
Treatment Program (NTP) at a median time of 41.5 days
(IQR 19–53) and 130 days (IQR 93.5–150.5), respect-
ively, who then had subsequent negative cultures in fol-
low up and were classed as microbiological cures.
“Adverse reaction/toxicity” was the reason given for
withdrawal in 3 of the 4 (75.0%) HIV-positive patients
and 3 of the 8 (37.5%) HIV-negative patients cured in
the NTP. One HIV-positive patient was referred to the
NTP after completing standard TB therapy in the trial
for further treatment because of disease relapse (and not
classed as a microbiological cure); however, none of the
HIV-negative patients were treated for relapse in this
matched sample.
Discussion
Our findings demonstrate that ART-naïve, HIV-positive,
smear-positive tuberculosis patients with CD4+ counts
> 250 cells/mm3 display fewer cavities on chest X-ray
despite similar sputum bacillary load and are more likely
to be anaemic before and at completion of treatment than
HIV-negative patients. HIV-positive patients were at
greater risk of toxicity during antituberculosis treatment
but not at greater risk of failing to achieve microbiological
cure than a matched sample of HIV-negative patients.
HIV-positive patients more frequently present with
pauci-bacillary disease and extra-pulmonary TB [3, 26, 27]
and, while this analysis detected a significant trend for ac-
tive TB without cavitation, it is noteworthy that the HIV-
positive patients in both the total and matched samples
did not differ significantly from the HIV-negative patients
in the time to positive result (TTP) of MGIT sputum cul-
ture at baseline. This suggests comparable burden of dis-
ease in both groups and argues against the accepted
Table 4 The ten most frequently reported TB-related symptoms in the matched analysis sample of HIV-positive and HIV-negative
patients. The number presented is the number of times a symptom was reported, and patients could not report a symptom more
than once at a visit. Symptom count taken from all scheduled visits in the REMoxTB database for these patients, and unscheduled
visits have been excluded. Percentages based on the total number of symptoms reported by these patients over the course of the
trial. Percentage of all symptoms reported at scheduled visits accounted for by row, according to HIV status, is shown in brackets
TB Symptom Frequency of Reported Symptoms
HIV-Positive (% of symptoms) HIV-Negative (% of symptoms)
Cough 104 (18%) 555 (19%)
Chest pains 84 (16%) 420 (15%)
Shortness of Breath 76 (13%) 331 (12%)
Fever 73 (13%) 350 (12%)
Night Sweats 76 (13%) 351 (12%)
Weight Loss 63 (11%) 294 (10%)
Haemoptysis 36 (6%) 137 (5%)
Respiratory Abnormalities 13 (2%) 101 (4%)
Loss of Appetite 8 (1%) 82 (3%)
Fatigue 10 (2%) 62 (2%)
Other 21 (4%) 2692 (6%)
Table 5 Regression coefficients from a multivariate model using
Zellner’s seemingly unrelated regression to test the effect of HIV
infection on the dependent variables measured at Week 0 and
Week 17. P values and 95% confidence intervals are provided
for the model estimations. The regression coefficient relates to
the effect of HIV-positive status on the outcome variable in a
linear regression equation, with a negative value indicating a
negative effect on the value of the outcome
Regression Coefficient 95% CIs P value
Haemoglobin
Week 0 Hb −0.05 −0.10 - 0.00 0.07
Week 17 Hb −0.05 −0.10 - 0.00 0.06
Weight
Week 0 Wgt 2.57 −1.24 - 6.38 0.19
Week 17 Wgt 1.71 −1.98 - 5.40 0.36
Symptoms
Week 0 Symp 0.04 −0.68 - 0.75 0.92
Week 17 Symp −0.59 −1.37 - 0.18 0.13
ALT Result
Week 0 ALT −0.06 −0.22 - 0.10 0.45
Week 17 ALT 0.00 −0.22 - 0.21 0.97
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maxim that HIV-positive patients present with less of a
bacillary load. While there should be a degree of caution
before applying these results to the wider HIV-positive
population, as there is a spectrum of disease severity pre-
dominantly according to the CD4+ count [28, 29], some
conclusions can be drawn. These findings confirm the im-
portance of testing all TB patients for HIV infection [25].
This is most relevant in resource-limited settings, where
constrained access to HIV testing can lead to testing only
cases with the highest clinical suspicion. However, conclu-
sions should be taken in light of the requirement that pa-
tients were smear positive at screening as this will have
acted to introduce bias by selecting out both HIV-positive
and HIV-negative patients with a lower bacillary burden.
The World Health Organisation (WHO) recommends
routine screening of HIV-positive patients for active TB
using a clinical algorithm of one or more of the follow-
ing symptoms: cough, fever, weight loss, or night sweats
[30, 31]. In a meta-analysis reviewing the individual pa-
tient-level data of HIV-positive patients with pulmonary
TB, the best-performing diagnostic strategy was the
presence of any one of these four symptoms [32]. This
meta-analysis demonstrated a sensitivity of 79% and a
specificity of 50% after including data for over 8000 pa-
tients, and the negative predictive value was 90% at 20%
prevalence of TB among HIV-infected individuals.
In the REMoxTB study chest pains, fever, cough, and
breathlessness were four of the most common symptoms
reported in the HIV-positive patients. These four symp-
toms collectively made up only 61% of the symptoms re-
ported, and weight loss accounted for just 14% of the
screening symptoms reported among the HIV-positive
group. The GeneXpert platform allows for the rapid iden-
tification of M tuberculosis in sputum (and other bodily
fluids) with a sensitivity of up to 75% even in cases of spu-
tum smear-negative pulmonary TB [33], and this also pro-
vides molecular results for the rifampicin resistance
profile of the organism. The WHO now recommend Gen-
eXpert as a first-line method for diagnosing active TB
[34]; however the infra-structure required to support this
technology has acted as a barrier to widespread imple-
mentation. The symptom data presented here shows a
poor sensitivity for the WHO-recommended screening
approach among these selected HIV-positive patients
(with higher CD4+ counts), and therefore lends support
to the argument that infra-structure development to allow
the use of existing, validated diagnostic technology in re-
source poor environments remains a priority [35].
HIV-positive patients in this sample were treated with
standard TB therapy lasting 6 months, and there was no
significant difference in the proportion of patients who
were cured 18 months after commencing therapy. The
most recent guidance from the Infectious Diseases Soci-
ety of America (IDSA) recommends extending TB
treatment to 9 months in cases where HIV-positive pa-
tients are not taking ART to reduce the risk of treatment
failure or relapse, and to treat with standard TB therapy
for 6 months if a patient is receiving ART [36]. While
the findings presented here are encouraging, with only
one case of relapse among the HIV-positive patients
meriting re-treatment following standard TB therapy,
these results must be interpreted with a degree of cau-
tion. The patient sample was small and there was a high
cure rate overall on standard TB therapy, and even in
the context of a matched population there is a risk that
a difference will be missed. Furthermore, previous work
has demonstrated a significant association between poor
treatment outcomes and adverse events in this study
population [37].
Coarsened exact matching (CEM) was adopted to
address the limitations of the small numbers in this
analysis, however there is still a risk that effect size
will be affected due to undetected sampling bias. A
further limitation to this analysis is the exclusion of
HIV-positive patients with a CD4+ count less than
250 cells/mm3, as this means that the rates of adverse
events should be considered to represent a favourable
scenario for patients not receiving ART. This should
also be noted when considering the data on clinical
change over time and microbiological outcomes. Un-
fortunately, this means that broader conclusions about
ART-naïve TB-HIV patients cannot be drawn from
this analysis. ART has been conclusively shown to im-
prove TB-HIV co-infected patients’ outcomes [38, 39],
and this paper does not disagree with the need for
early ART in these patients despite the reassuring
treatment outcomes.
Conclusions
The increased risk of adverse events associated with HIV
infection has implications for clinical monitoring of
these patients and this work which studies a patient co-
hort with a relatively high CD4 count, confirms the need
for clinicians to ensure that TB programmes focus on
this high-risk group even in cases where the CD4+ is
preserved. The treatment outcomes among the HIV-
positive and HIV-negative patients were similar with 6
months of standard TB therapy in this matched popula-
tion, and those patients who required longer durations
of therapy were identified early in treatment. TB therapy
is particularly toxic for HIV-positive patients, and this
would suggest that those patients performing well clinic-
ally do not need to be exposed to a longer duration of
drugs and the concomitant risk of further toxicity. In fu-
ture Phase III TB trials it will be critical that recruitment
and monitoring of HIV-patients is undertaken with suffi-
cient accuracy to translate into real clinical benefit for
this often under-served patient population.
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